Allergy and clinical immunology practices operate two parallel business models under one roof: a high-volume procedural service (allergen immunotherapy injections, skin testing, challenge procedures) and a complex biologic management practice (severe asthma, chronic urticaria, eosinophilic esophagitis, atopic dermatitis). Each model has its own administrative demands, and together they create a workload that routinely overwhelms in-house staff who are not organized to manage both simultaneously.
Virtual assistants with allergy-immunology training are helping practices build the administrative capacity to execute both service lines without constant staff overload.
Allergen Immunotherapy Injection Series: The Scheduling Engine
Subcutaneous allergen immunotherapy (SCAIT) involves a buildup phase of escalating antigen doses administered at weekly intervals, followed by a maintenance phase with monthly injections for three to five years. Managing the scheduling for a panel of 200 to 500 active AIT patients—tracking where each patient is in the buildup sequence, rescheduling missed appointments to prevent dose advancement delays, coordinating the 30-minute post-injection observation period, and managing vial refills—is a continuous operational challenge.
VAs manage the AIT scheduling engine by maintaining each patient's current buildup position, sending appointment reminders with pre-visit instructions, rescheduling missed doses per protocol (restart versus reduced dose depending on the interval missed), and alerting the clinical team when a patient is ready to advance to the maintenance phase. For practices running sublingual immunotherapy (SLIT) programs, VAs track shipment timelines and coordinate refill orders.
The AAAAI reports that adherence to immunotherapy schedules is a primary determinant of clinical efficacy—yet scheduling complexity is among the top cited reasons for patient dropout. Systematic VA management of the scheduling workflow directly addresses this adherence driver.
Venom and Food Challenge Coordination
Venom immunotherapy initiation requires confirmatory venom-specific IgE or skin testing, followed by graded venom challenges in some protocols. Food oral immunotherapy (OIT) and food challenges require dedicated appointment blocks, anaphylaxis management preparation, and detailed pre-challenge patient instructions. These procedures require more coordination per patient than standard office visits and cannot be managed effectively through standard appointment scheduling alone.
VAs coordinate the challenge workflow: scheduling the dedicated time blocks, sending multi-step pre-procedure instructions, confirming the patient is off antihistamines for the required washout period, and preparing the pre-challenge documentation packet. For food OIT programs, VAs manage the buildup schedule and dosing calendar with the same systematic approach used for SCAIT, tracking each patient's current dose level and coordinating updosing appointments.
IgE Panel Result Tracking
Total and specific IgE testing panels are central to allergy diagnosis and biologic eligibility determination. Total IgE levels are required for Xolair (omalizumab) dosing calculations, and specific IgE results guide immunotherapy allergen selection and treatment monitoring. In a busy allergy practice, results from multiple reference labs arrive asynchronously and must be reviewed in clinical context and linked to the patient's ongoing care plan.
VAs maintain an IgE result tracking log, route incoming panel results to the ordering provider with the patient's prior results for longitudinal comparison, and flag total IgE values relevant to biologic dosing calculations. For patients being considered for omalizumab, VAs verify that total IgE and weight are documented in the format required for the payer's prior authorization submission.
Dupixent and Xolair Prior Authorization for Severe Asthma and Atopic Conditions
Biologics for type 2 inflammatory diseases—dupilumab (Dupixent), omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), tezepelumab (Tezspire)—each have distinct payer criteria. For dupilumab in severe asthma, documentation of eosinophil count, failed ICS/LABA therapy, and exacerbation history is required. For omalizumab, total IgE, weight, and allergen sensitization documentation are mandatory components. Payer formulary positioning shifts frequently, and prior authorization requirements can change within plan year.
VAs maintain a biologic authorization matrix for each major payer, track authorization expiration dates for patients on maintenance biologic therapy, and assemble renewal submissions before expiration. For new starts, VAs identify the appropriate biologic based on the physician's documented rationale and build the submission package from the chart documentation—reducing the time from prescription intent to authorization approval.
Scaling the Allergy Immunology Practice Without Scaling Overhead
The AAAAI projects continued growth in allergy and asthma prevalence driven by environmental and lifestyle factors. Practices that can manage growing AIT panels, offer food challenge and OIT services, and administer the expanding biologic formulary will capture that growth—but only if their administrative infrastructure scales with the clinical volume.
Allergy and immunology practices can explore dedicated VA support for AIT, challenge coordination, and biologic prior authorization at Stealth Agents.
Sources
- American Academy of Allergy, Asthma & Immunology. Allergen Immunotherapy: Clinical Practice. aaaai.org, 2024.
- Cox L, et al. "Allergen Immunotherapy: A Practice Parameter Third Update." Journal of Allergy and Clinical Immunology, 2011.
- Global Initiative for Asthma. GINA 2024 Report: Global Strategy for Asthma Management. ginasthma.org.
- Prescribing information for dupilumab (Dupixent), omalizumab (Xolair). Sanofi/Regeneron, Genentech/Novartis.